ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1469	National Cancer Institute	Html	en	Adult Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of adult central nervous system tumors.	type anaplastic astrocytomas 0.549962 5-year analysis 0.459034 rapid immunohistochemical analysis 0.458442 mutations aids diagnosis 0.4781 adjuvant temozolomide 0.53303 BRAF genetic alterations 0.471994 pontine gliomas 0.467631 concurrent radiation therapy 0.474706 MGMT promoter methylation 0.572789 Radiation Therapy Oncology 0.484458 oligodendroglial tumors 0.468432 adult high-grade glioma 0.464776 Nervous System Tumors 0.717497 Astrocytic Tumors Treatment 0.922097 diffuse astrocytomas 0.480334 prognostic factor 0.47815 patients 0.62456 Primary Central Nervous 0.835704 Tumor Type section 0.826321 low-grade gliomas 0.476475 randomized trials 0.48238 anaplastic gliomas 0.467716 Treatment Option Overview 0.469049 standard systemic chemotherapy 0.485413	mutant tumors 0.500547 malignant gliomas 0.567609 radiation therapy 0.833741 standard chemotherapy agent 0.48857 Lancet Oncol 0.46722 glioblastoma patients 0.504986 Radiation Therapy section 0.489765 deep-seated tumors 0.489355 Glioblastomas treatment section 0.511285 diffuse gliomas 0.494198 CNS tumors 0.489107 strong prognostic factor 0.47196 primary malignant glioma 0.474955 DNA repair enzyme 0.549791 standard local treatment 0.596897 Low-grade tumors 0.493795 oral agent temozolomide 0.522443 pilocytic astrocytomas 0.562223 particular glioma subtypes 0.489447 newly diagnosed glioblastoma 0.602836 activating point mutation 0.473461 Tumors Treatment section 0.972163 mutant-specific IDH1 antibody 0.464835 potential diagnostic utility 0.459778	CLICK HERE
1751	National Cancer Institute	Html	en	Hospice Care	A fact sheet about hospice care, including insurance coverage.	palliative care share 0.4463 home health 0.436046 hospice programs 0.663338 hospice team 0.740949 specific care decisions 0.42786 hospice doctor 0.624846 spiritual support 0.408056 public health departments 0.391127 American Cancer Society 0.455655 hospice services 0.722561 home health aides 0.405139 state Medicaid office 0.402126 nursing care 0.391635 hospice medical director 0.768439 Hospice Association 0.649826 cancer care 0.409838 hospital business office 0.388593 life expectancy 0.408587 hospice team member 0.685192 special in-patient facilities 0.500987 Medicare website 0.415518 specific state locations 0.392604 government health insurance 0.402081 sheet Palliative Care 0.444628 state social services 0.40519	nursing homes 0.407681 end-of-life care 0.424373 health aide services 0.410795 hospice organizations 0.592662 Palliative Care Organization 0.507564 private insurance plans 0.399019 Hospice Net 0.623257 palliative care 0.604188 Medicare coverage 0.386456 national hospice 0.673933 regional home health 0.398589 national hospice programs 0.634262 hospice care 0.982488 local state welfare 0.391739 health insurance plans 0.419219 Medicare benefits 0.388255 hospice expenses 0.700651 insurance plans 0.503978 federal-state partnership program 0.389089 Medicare Hospice Benefits 0.695621 Medicare-certified hospice programs 0.660409 Respite Care page 0.429976 social work services 0.407475 free fact sheets 0.38648	CLICK HERE
1910	National Cancer Institute	Html	es	Tratamiento de los tumores carcinoides gastrointestinales (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los tumores carcinoides gastrointestinales.	tejido tumoral carcinoide 0.303641 electrodos minúsculos 0.300961 tumor carcinoide 0.379006 siguientes procedimientos 0.32226 pequeña cámara 0.300969 pequeña cantidad 0.300995 claro cuál 0.301673 rayos x 0.301155 tumores carcinoides gi 0.541315 cromogranina a 0.301286 ondas sonoras 0.301178 síndrome carcinoide 0.405552 pequeño efecto 0.300747 tumores neuroendocrinos 0.31718 National Cancer Institute 0.300501 tumores carcinoide gi 0.305034	siguientes riesgos 0.300555 endocrina múltiple tipo 0.30275 Instituto Nacional 0.300956 PDQ Tratamiento 0.301284 neurofibromatosis tipo 0.301611 tubo gi 0.311684 Physician Data Query 0.302032 pimientos chili 0.300797 carcinoides gi recidivantes 0.302839 Antecedentes familiares 0.301159 cuerpo cantidades 0.303122 hígado ayuda 0.301344 tumores carcinoides 0.989957 tumor carcinoide gi 0.311705 siguientes sumarios 0.303432 células neuroendocrinas 0.30282	CLICK HERE
1967	National Cancer Institute	Html	es	Tratamiento del cáncer de pene (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de pene.	siguientes procedimientos 0.765966 siguientes aspectos 0.663436 radiosensibilizadores ayuda 0.608332 estadio ii 0.653561 ganglio linfático centinela 0.99757 rayos x 0.61452 menor cantidad 0.630187 enlace drugs approved 0.616023 ondas sonoras 0.614903 National Cancer Institute 0.60451 siguientes riesgos 0.604706 papiloma virus 0.656514 únicos tratamientos 0.60726	Instituto Nacional 0.609778 Penile Cancer 0.60882 estadio iiia 0.623114 PDQ Tratamiento 0.608893 cuerpo esponjoso 0.725663 presente sección 0.608144 Physician Data Query 0.620917 siguientes sitios 0.675658 siguientes operaciones 0.617884 órgano masculino 0.616691 siguientes pruebas 0.65372 siguientes estadios 0.621615	CLICK HERE
2080	National Cancer Institute	Html	es	Exámenes de detección del cáncer de testículo (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de testículo.	estadios tardíos 0.651471 Visuals Online 0.570773 PDQ Exámenes 0.759721 Physician Data Query 0.918778 testículos.ampliar anatomía 0.643812 mejores tratamientos 0.631067 prevención revisa 0.590052	sistema urinario masculino 0.76274 glándulas sexuales masculinas 0.790025 información ayuda 0.600632 National Cancer Institute 0.62598 siguientes riesgos 0.575127 Instituto Nacional 0.738066	CLICK HERE
2109	National Cancer Institute	Html	es	Prevención del cáncer de esófago (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre los factores que pueden influir en el riesgo de cáncer de esófago y sobre la investigación dirigida a la prevención de esta enfermedad.	siguientes factores 0.969759 voluntarios sanos 0.42115 Physician Data Query 0.489663 Estados Unidos 0.430297 libre uso 0.411941 suficiente ejercicio 0.429799 prevención revisa 0.420955	PDQ Prevención 0.433383 carcinoma epidermoide 0.463013 National Cancer Institute 0.420887 siguientes riesgos 0.416828 siguientes sumarios 0.467407 Instituto Nacional 0.441845	CLICK HERE
3880	National Cancer Institute	Html	es	Extractos de muérdago (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de los extractos de muérdago como tratamiento para personas con cáncer.	from mistletoe extract 0.31162 Cancer Res Clin 0.306787 mistletoe extracts 0.396569 album extract isorel 0.309539 Mistletoe extracts standardised 0.30709 viscum album 0.980886 galactoside-specific lectin from 0.335383 thionins from viscum 0.3152 muérdago i 0.308032 treated with viscum 0.312029 Cancer Res 0.31513 isolated from viscum 0.307496 extracto viscum album 0.308065 Viscum album agglutinin-induced 0.308373 with viscum album 0.33586 from viscum album 0.472392 beta-galactoside-specific lectin from 0.310754 Hajto T 0.314595 extract from viscum 0.316835 Viscum album enhancing 0.30854 patients with 0.307472 thionins from european 0.306901 Immunomodulatory Agents from 0.306741 viscum album extract 0.338924 viscum album l 0.601922	Mistletoe lectins as 0.306952 preparation from viscum 0.308802 Complement Ther Med 0.308742 tumor cell 0.31334 Mistletoe extracts standardized 0.30726 Beuth J 0.317637 mistletoe treatment 0.310143 lectin from 0.350339 derived from viscum 0.315008 In vitro effects 0.312037 Schaller G 0.307482 blood mononuclear cells 0.315901 subspecies viscum album 0.308835 lectin from viscum 0.322905 Gabius HJ 0.329931 Viscum album induces 0.316269 ml1 from viscum 0.307567 breast cancer 0.326075 Viscum album species 0.308916 plant lectin 0.306716 mistletoe lectins 0.449053 in vitro 0.456679 Hostanska K 0.309958 fermented extract from 0.30821	CLICK HERE
15645	National Cancer Institute	Html	en	Legal Requirements	Research grants are subject to many requirements from a variety of legal authorities, with the broadest being the U.S. Constitution.	Grants Management Officer 0.556816 United States Code 0.420323 research grants 0.615532 basic substantive legislation 0.444546 program requirements 0.352641 to-date policy guidance 0.408228 general regulations 0.340444 federal agency 0.352362 federal regulations 0.501493 Administrative Procedures Act 0.389735 NIH standard terms 0.534403 NIH Grants Policy 0.868204 research grant policies 0.404926 reasonable conditions 0.340026 research community 0.390073 appropriation legislation 0.37075 individual grants 0.462407 Appropriation bills 0.343865 NIH contracting offices 0.525598 legal authorities 0.328189 issues government-wide circulars 0.425727 administrative requirements 0.328069 NCI grants 0.592028 human subjects protection 0.399778 grants administration policies 0.567751	Congress 0.346023 authorize federal agencies 0.500849 United States 0.452601 CFR Parts 0.368971 grants administration decisions 0.591481 federal Executive agencies 0.452185 CFR 0.384291 appropriation laws 0.351099 Spending Power Clause 0.442228 United States Constitution 0.43014 grants administration 0.689773 grants area 0.524071 appropriate NIH oversight 0.528865 grants 0.962134 program expenditures 0.33855 requirements 0.388492 NIH Guide 0.647123 federal register 0.490568 federal assistance funds 0.682098 specific laws 0.335616 specific program 0.335203 federal program 0.371737 Public Health Service 0.421913 general authority 0.329535	CLICK HERE
16162	National Cancer Institute	Html	en	New Therapies Are Changing the Outlook for Advanced Melanoma	An article about a host of new treatment options that have been produced in the last several years for patients with the skin cancer melanoma.	improved progression-free survival 0.366558 new therapies 0.351845 target BRAF proteins 0.357172 commonly used therapies 0.342946 BRAF inhibitor 0.43187 BRAF mutations 0.802264 Cancer Therapy Evaluation 0.357896 Overall survival results 0.381093 Dr. Schuchter 0.658164 overall survival 0.53856 clinical trials 0.561097 results 0.412771 median progression-free survival 0.364224 clinical trial 0.629151 median overall survival 0.359384 patients 0.941423 recent FDA-approved drugs 0.349384 tumor responses 0.376799 metastatic melanoma 0.378989 chemotherapy drug dacarbazine 0.34213 median survival 0.400006 melanoma specialist 0.389264 large clinical trial 0.469476 MEK inhibitor 0.413513	cancer cells 0.348742 Patient tumor samples 0.353483 skin-related side effects 0.386676 MEK inhibitor cobimetinib 0.40543 clinical trial participants 0.357541 BRAF-MEK inhibitor combination 0.3755 Dr. Streicher 0.487979 tumor cells 0.429743 checkpoint inhibitor 0.371337 small clinical trials 0.342687 drugs 0.41439 progression-free survival 0.707667 MEK inhibitors 0.605005 advanced melanoma 0.87481 PD-1 inhibitor 0.342866 recent clinical trials 0.345485 new treatment options 0.457424 tumors 0.426135 New Melanoma Therapies 0.48664 early-phase clinical trial 0.367414 Moffitt Cancer Center 0.358773 regulatory approval 0.407964 Pennsylvania Abramson Cancer 0.343564 skin cancer melanoma 0.49678	CLICK HERE
16380	National Cancer Institute	Html	es	Toxicidad financiera del tratamiento del cáncer (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del riesgo de sufrir dificultades financieras durante el tratamiento del cáncer.	among patients with 0.356148 National Health Interview 0.33762 survivors identified through 0.3506 Guy GP Jr 0.797953 Targeted Cancer Therapies 0.346578 seguro médico 0.502578 Cancer Care Outcomes 0.395905 Medical Debt And 0.338028 Care Outcomes Research 0.337105 cancer care 0.484521 Adult Cancer Survivors 0.410356 Ekwueme DU 0.389597 estudio cancer care 0.350705 burden among 0.343127 Health Interview Survey 0.341695 Blough D 0.351854 Natl Cancer Inst 0.34743 cáncer versus 0.347441 Medicare Current Beneficiary 0.347647 cancer survivors 0.793538 Duke Cancer Institute 0.343096 with cancer 0.974917 patients with 0.384813 Medicare beneficiaries with 0.362941 Dowling EC 0.336978	Hardship Associated With 0.350445 United States 0.354013 financial hardship 0.453927 experiences with cancer 0.407883 Financial Hardship Associated 0.350297 Health Aff 0.447932 Care Cancer 0.350503 associated with cancer 0.462553 Debt And Bankruptcy 0.341472 Yabroff KR 0.591176 medical expenditure 0.337994 For Working-Age Cancer 0.400083 out-of-pocket health care 0.387866 Working-Age Cancer Survivors 0.410894 Clin Oncol 0.748582 breast cancer 0.503347 Rectal Cancer 0.343774 Non-elderly Cancer Survivors 0.355648 cáncer problemas 0.341283 financial toxicity 0.423332 patients receiving adjuvant 0.339287 MEPS Experiences with 0.352286 Current Beneficiary Survey 0.336425 expenditure burden 0.396505	CLICK HERE